The 2025 financial year has been a period of significant growth, strategic evolution, and clinical impact for the TOGA. As we release our 2025 Annual Report, we reflect on the past five years defined by our commitment to multidisciplinary innovation and the strengthening of our research community across Australia and New Zealand.
TOGA reported a solid financial outcome for the year ended 30 June 2025, reflecting continued operational strength and prudent management. These results ensure we are well-positioned to support our strategic objectives in the years ahead. Furthermore, our fundraising efforts reflected the profound generosity of our community, raising a total of $122,340 to support vital research.
This year also marked the launch of TOGA’s Strategic Plan for 2025–2028. Building upon the strong foundation established during our first five years, this new three-year roadmap focuses on four critical pillars: driving research excellence, funding and supporting the next generation of research leaders, engaging effectively with our growing membership and expanding our expertise and impact across research and education.
Membership and Education
Our strength has always been our people. We are proud to report that the TOGA membership grew to 540 members at the end of the 2025 financial year, representing a 6% increase on 2024 figures. Our community now spans 26 disciplines with representation from every Australian state and New Zealand, reinforcing our commitment to a truly multidisciplinary approach to thoracic oncology.
For the first time in TOGA’s history, the Annual Scientific Meeting was held in Brisbane. Convened by A/Prof Bryan Chan from the Sunshine Coast University Hospital, the event centered on the theme: ‘Implementing Change in Thoracic Cancer Care Through Multidisciplinary Innovation.’ The meeting saw 416 attendees gather to share insights, hear from global experts, and collaborate on the future of patient care.
Research and Clinical Trial Milestones
Our Working Groups remained a hive of activity this year, reviewing 21 research concepts. Of these, 19 received formal endorsement, a testament to the high calibre of innovation within our membership.
Several key trials also achieved major milestones:
SHERLOCK: Recruitment was completed this year, with results proudly presented at the 2025 World Conference on Lung Cancer.
DYNAMALK: Enrolment was completed in July 2025, successfully recruiting 61 participants over 20 months.
ILLUMINATE: The trial evaluating durvalumab and tremelimumab with platinum-pemetrexed in metastatic NSCLC post-EGFR TKI progression has now reached publication.
Consumer-Led Research Priorities
Our Consumer Panel developed an inclusive process to gather and refine research ideas from both panel members and the wider consumer group. Through a collaborative voting and discussion process, two key research priorities were identified for the coming year:
Management of brain metastases and the development of clinical guidelines.
Research into leptomeningeal disease in lung cancer.
We thank our members, donors, and partners for their unwavering support as we work together to improve outcomes for those affected by thoracic cancers.
To read the full details of our progress, read or download the TOGA 2025 Annual Report below.
